<DOC>
	<DOC>NCT02978326</DOC>
	<brief_summary>This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the efficacy, safety and pharmacokinetics of SAGE-217 in up to 32 adult female subjects diagnosed with severe postpartum depression.</brief_summary>
	<brief_title>A Study to Evaluate SAGE-217 in Subjects With Severe Postpartum Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression, Postpartum</mesh_term>
	<criteria>Key Subject either must have ceased lactating at screening or, if still lactating or actively breastfeeding at screening, must agree to temporarily cease giving breast milk to her infant(s) Subject has had a Major Depressive Episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by the Structured Clinical Interview for DSMIV Axis I Disorders (SCIDI) Subject is â‰¤ six months postpartum Key Active psychosis Attempted suicide associated with current episode of postpartum depression Medical history of seizures Medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder. Note: suicidal ideation is not an exclusion. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Postpartum Care</keyword>
</DOC>